Under construction – not a live service
Sign in
Taking people in FranceNo phase

Safety Pilot of ExOlin in Type 1 Diabetes With Unstable Blood Sugar

Tests the ExOlin device safety in adults with type 1 diabetes and unstable blood sugar.

Key facts

Who runs it
Defymed
Where
Strasbourg, FranceSee the site
Registry title
Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes
Status
Recruiting
People taking part
8 people, planned
Started
5 May 2022
Expected to end
Apr 2027
Type of study
Interventional
Treatments tested
  • ExOlin®
  • Insulin aspart
Record updated
27 July 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 diabetes whose blood sugar is poorly controlled, with big swings and a risk of severe low blood sugar. It tests the safety of ExOlin®.

Age
18 years or older
Sex
Men and women
Disease stage
Type 1 diabetes for more than 2 years, with HbA1c above 7.0% (53 mmol/mol) and below 12.0% (108 mmol/mol). Also needs severe low blood sugar in the past 12 months, or frequent large blood sugar swings in the past month, or side effects of insulin under the skin (insulin resistance or skin fat problems).
Earlier treatment
Must have used an insulin pump and a Dexcom G6 continuous glucose monitor for at least 3 months. Cannot have had corticoid treatment in the 4 weeks before joining, or an investigational product in the 12 weeks before joining.
Biomarker or test result
Body mass index above 16 kg/m2 and below 35 kg/m2.

Main reasons for not taking part

  • Kidney filtration rate below 30 mL/min/1.73m2
  • Weakened immune system, or active infection or inflammation
  • Ongoing blood-thinning (anticoagulant) treatment
  • Pregnant, breastfeeding, or planning a pregnancy
  • Unstable diabetic eye disease, or cancer not resolved within the past 5 years (some exceptions)

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Adult men or women (age ≥ 18 years)
  • Diagnosis of Type 1 Diabetes (T1D) for more than 2 years at the start of screening
  • Body mass index (BMI) > 16 kg/m2 and < 35 kg/m2
  • Well managed intensive SubCutaneous (SC) insulin therapy, i.e. patient using for at least 3 months:; CSII, whatever the insulin pump used, and; Continuous Glucose Monitoring (CGM), by using Dexcom G6
  • 7.0% < Serum HbA1c < 12.0%
  • Patient characterized by one of the following conditions:; Unstable diabetes/poor glycemic control, meaning patient presenting:; at least one episode of severe hypoglycemia during the 12 months prior to study screening. Severe hypoglycemia is defined by American Diabetes Association (ADA) standards as "severe cognitive impairment requiring assistance from another person for recovery" (as per ADA's definition in "standards of care in diabetes"); or glycemic excursions (post-prandial hyperglycemic or nocturnal hypoglycemic episodes) considered as too frequent and of high amplitude by the investigator, during the previous month; Presence of adverse side effects of SC insulin-therapy:; SC insulin resistance; or severe acquired lipodystrophy resistant to pump treatment; or genetic skin atrophy or lipodystrophy

Who cannot take part

  • Ongoing active anticoagulant therapy
  • Unstable diabetic retinopathy (as per ophthalmologist's review within 6 months before screening)
  • Known active alcohol or drug abuse
  • Having received corticoid treatment within 4 weeks prior to enrollment
  • Having received an investigational product within 12 weeks prior to enrollment, or currently participating in another clinical trial, with the exception of observational / non-interventional; registries, for which written prior approval of Defymed is needed
  • Women planning for pregnancy, being pregnant or breastfeeding or unwilling to use adequate contraceptive methods for the duration of the study (oral hormonal contraceptives, implants, injectables, hormonal or copper intrauterine device, or vasectomized partner)
  • Renal glomerular filtration rate <30 mL/min/1.73m2 as per Chronic Kidney Disease - Epidemiology Collaboration (CDK-EPI) calculation
  • Active infection or inflammation
  • Known history of skin affliction that could impact ExOlin® tolerance
  • Known allergy to one of the devices' components, including known allergy to fixation systems (e.g. patch, plaster) for SC administration devices such as external pumps and CGM, or chronic allergy related to prolonged wearing of such systems
  • Known allergy to insulin NovoRapid®
  • Known allergy to anesthetics, or products containing iodine and its derivates, or antibiotics used during surgery (cefazolin, and combination of clindamycin and gentamycin)
  • Cardiac condition incompatible with surgery requirements as per anesthesiologist's opinion
  • Current or history of unresolved malignancy within 5 years before screening (with exceptions for squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast carcinoma without lymph node metastases, well-differentiated thyroid carcinoma or other non-invasive lesion that, in the opinion of the investigator, is considered as cured with minimal risk of recurrence within 5 years)
  • Other surgical or medical condition that, in the judgment of the investigator, might warrant exclusion or be contraindicated, like for instance visual or hand-use symptoms
  • Mental handicap or psychiatric condition incompatible with appropriate handling of devices or compliance to treatment or investigation-related tasks
  • Unwilling to give written informed consent to participation in the study, or unable to do so for psychiatric, cognitive or linguistic reasons
  • Immunocompromised patient
  • Local or systemic acute or chronic inflammation (rheumatoid arthritis, sclerodermia)
  • Severe wound healing issues
  • Parietal reinforcement prostheses
  • Activity contraindicated as per external pump and CGM use recommendations
  • Patient willing to practice activities with risks of trauma or major change in the environment pressure such as combat sport or scuba diving
  • Person under guardianship, trusteeship or deprived of liberty
  • Person not affiliated to one of the French social security systems

Where in France

  • Hopitaux Universitaires de StrasbourgStrasbourg, FranceContact: Nathalie Jeandidier, MDTaking people

About the trial

What the trial wants to find out

First in Human, pilot investigation An Open Label, Monocentric, Pilot Study Evaluating Safety of ExOlin® in Patients with Poorly Controlled Type 1 Diabetes with High Glucose Fluctuations, Prone to Severe Hypoglycemia

The group in the trial

  • test armTreatment being tested

    All patients will be enrolled in same arm which contains the two interventions (device + drug) and follow mandatory phases of trial: screening, implantation, treatment with ExOlin, explantation.

    Treatment: ExOlin® and Insulin aspart

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Open Label, Monocentric, Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes With High Glucose Fluctuations, Prone to Severe Hypoglycemia
Plain-language title
Safety Pilot of ExOlin in Type 1 Diabetes With Unstable Blood SugarGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 July 2022